- The US FDA has classified its inspection of Unit-VI of Apitoria Pharma, Aurobindo Pharma's wholly owned subsidiary, as Voluntary Action Indicated (VAI).
- Unit-VI is an API (active ingredient) plant at Parawada, Anakapalli district, Andhra Pradesh. The FDA inspected it from 24 to 28 August 2026 and made 3 observations.
- Aurobindo says the plant has received the FDA's Establishment Inspection Report and the inspection is now closed.
What it means for Aurobindo's business
The inspection is behind it
- With VAI status and the inspection closed, the FDA does not plan any regulatory action against the plant over this inspection.
Supply carries on
- An API plant makes the active ingredients that go into medicines. The outcome lets Unit-VI keep supplying them without an FDA restriction from this inspection.
Fixes are its own to make
- VAI means Aurobindo is expected to correct the 3 observations itself, without FDA enforcement.
What the filing says
The plant
- Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary of Aurobindo Pharma.
- An API manufacturing facility at E-Bonangi Village, Parawada Mandal, Anakapalli district, Andhra Pradesh.
The inspection
- The US FDA inspected the plant from 24 to 28 August 2026, ending with 3 observations. Aurobindo reported this on 28 August 2026.
The outcome
- The unit has received the Establishment Inspection Report (EIR), classifying it as Voluntary Action Indicated (VAI).
- The FDA has concluded that the inspection is closed. Aurobindo filed this on 21 November 2026.
Why it matters
What VAI means
- Voluntary Action Indicated means the FDA found issues but does not plan regulatory action; the company corrects them itself.
- It is the middle of the FDA's three outcomes: No Action Indicated (NAI), VAI and Official Action Indicated (OAI).
What an EIR is
- The Establishment Inspection Report is the FDA's written report of an inspection. Its classification is the FDA's view on how the inspection ended.
What the filing does not say
- It does not say what the 3 observations were, which ingredients the plant makes, or how much of Aurobindo's sales depend on it.
What to watch next
- Comments on Apitoria's US supply in Aurobindo's next quarterly results.
Funds that hold Aurobindo
- Quant ELSS Tax Saver Fund8.8% of the fund
- SBI Midcap Fund2.3% of the fund
- HDFC Mid Cap Fund2.2% of the fund
- UTI Mid Cap Fund2.2% of the fund
- SBI Large & Midcap Fund2.0% of the fund
- SBI Flexicap Fund1.7% of the fund
- SBI ELSS Tax Saver Fund0.84% of the fund
- SBI Multi Asset Allocation Fund0.79% of the fund
- HDFC Balanced Advantage Fund0.45% of the fund
- Quant Small Cap Fund0.44% of the fund
and 3 more
From each fund house's October 2026 portfolio.
Source: Exchange filings
Aurobindo: questions
What did the US FDA decide on Aurobindo's Apitoria Unit-VI?
It classified the August 2026 inspection as Voluntary Action Indicated (VAI) and closed it, according to Aurobindo's 21 November 2026 filing.
What does the VAI status mean for Aurobindo's business?
The API plant faces no FDA regulatory action from this inspection and can keep supplying as before. Aurobindo is expected to fix the 3 observations on its own.
What is Apitoria Pharma?
A wholly owned subsidiary of Aurobindo Pharma. Its Unit-VI is an active pharmaceutical ingredient (API) plant in Anakapalli district, Andhra Pradesh.
How many observations did the FDA make at Apitoria Unit-VI?
Three, at the end of the inspection held from 24 to 28 August 2026.
This page is educational research based on company filings. It is not a recommendation to buy or sell any security or fund, or personalised investment advice. Investments in securities market are subject to market risks. Read all related documents carefully before investing. Registration granted by SEBI, enlistment with IAASB and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.


